32 unchanged sentences
• Patent litigation is not uncommon in the medical device industry, and we may be subject to such litigation.
−Removed: • We may be subject to damages resulting from claims that we have wrongfully used or disclosed patient health information or trade secrets, or are in breach of non-competition or non-solicitation agreements.
+Added: • We may be subject to damages resulting from claims that we have wrongfully used or disclosed patient health information, personal information, or trade secrets, or are in breach of non-competition or non-solicitation agreements.
Risks Related to Our Legal and Regulatory Environment
13 unchanged sentences
Since our inception in January 2006, we have incurred a significant net loss.
−Removed: As of June 30, 2022, we had an accumulated deficit of $664.4 million.
+Added: As of September 30, 2022, we had an accumulated deficit of $713.3 million.
To date, we have funded our operations primarily through cash collected from product sales, private and public offerings of our equity securities, and debt financing.
448 unchanged sentences
We may need or otherwise determine to raise additional funds in the future and if we are unable to raise additional funds when necessary or desirable, we may not be able to achieve our strategic objectives.*
−Removed: As of June 30, 2022, we had $635.3 million in cash, cash equivalents and short-term investments.
+Added: As of September 30, 2022, we had $608.7 million in cash, cash equivalents and short-term investments.
Our management expects the continued growth of our business, including the expansion of our customer service infrastructure to support our growing base of customers, our plans to expand commercial sales of our products outside of the United States, the growth of our manufacturing and warehousing operations, increasing the size of our facility footprint due to increases in headcount and additional R&D activities, will continue to increase our expenses.
43 unchanged sentences
We rely primarily on patent, trademark and trade secret laws, as well as confidentiality and non-disclosure agreements, to protect our proprietary technologies.
−Removed: As of June 30, 2022, our patent portfolio consisted of approximately 125 issued U.S.
+Added: As of September 30, 2022, our patent portfolio consisted of approximately 127 issued U.S.
patents and 82 pending U.S.
334 unchanged sentences
A takeover of the Company would trigger an option of the holders of the Notes to require us to repurchase the Notes.
−Removed: In addition, if a make-whole fundamental change (as defined in the indenture) occurs prior to the maturity date of the Notes, we will, in some cases, be required to increase the conversion rate of the Notes for a holder that elects to convert its Notes in connection with such make-whole fundamental change.
+Added: In addition, if a make-whole fundamental change (as defined in the indenture governing the Notes) occurs prior to the maturity date of the Notes, we will, in some cases, be required to increase the conversion rate of the Notes for a holder that elects to convert its Notes in connection with such make-whole fundamental change.
These and other provisions set forth in the indenture may have the effect of delaying or preventing a takeover of the Company.
18 unchanged sentences
Date of First Filing Exhibit Number
−Removed: 10.1 Credit Agreement Between Tandem Diabet es Care, Inc., and Bank of America , N.A.
10.1* Confidential Intellectual Property Agreement, dated July 10, 2012, by and between Tandem Diabetes Care, Inc.
and Smiths Medical ASD, Inc.
+Added: 10-Q 001-36189 03-Aug-2022 10.2
31.1 Certification of John F.
8 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: 101.INS XBRL Instance Document.
−Removed: 101.SCH XBRL Taxonomy Extension Schema Document.
−Removed: 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.
−Removed: 101.DEF XBRL Taxonomy Extension Definition Linkbase Document.
−Removed: 101.LAB XBRL Taxonomy Extension Label Linkbase Document.
−Removed: 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: 101.INS Inline XBRL Instance Document.
+Added: 101.SCH Inline XBRL Taxonomy Extension Schema Document.
+Added: 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
+Added: 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
+Added: 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (embedded within the Inline XBRL Document contained in Exhibit 101).
+Added: * Certain confidential portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because the registrant has determined that such redacted information is (i) not material, and (ii) is the type of information the registrant treats as private or confidential.
+Added: If requested by the Commission or the Staff, the registrant will promptly provide, on a supplemental basis, an unredacted copy of this exhibit and its analysis with respect to the materiality and confidentiality of the redacted information.
** This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.
−Removed: ** Confidential treatment has been granted with respect to certain portions of this exhibit pursuant to an application for confidential treatment sent to the Securities and Exchange Commission.
−Removed: Such portions are omitted from this filing and have been filed separately with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Tandem Diabetes Care, Inc.
−Removed: Dated August 3, 2022
+Added: Dated November 2, 2022
President and Chief Executive Officer
1 unchanged sentence
Principal Executive Officer)
−Removed: Dated August 3, 2022
+Added: Dated November 2, 2022
Executive Vice President, Chief Financial Officer and Treasurer
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.